KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Interest & Investment Income (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Interest & Investment Income for 13 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 43.32% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.8 million through Dec 2025, down 36.04% year-over-year, with the annual reading at $26.8 million for FY2025, 36.04% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $5.3 million at Xenon Pharmaceuticals, down from $6.2 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $11.4 million in Q1 2024, with the low at $57000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $5.3 million, with a median of $5.8 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 92.11% in 2021, then soared 5278.95% in 2022.
  • Over 5 years, Interest & Investment Income stood at $191000.0 in 2021, then skyrocketed by 2236.65% to $4.5 million in 2022, then surged by 94.73% to $8.7 million in 2023, then grew by 8.41% to $9.4 million in 2024, then plummeted by 43.32% to $5.3 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $5.3 million, $6.2 million, and $7.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.